Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Status:
Withdrawn
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally
bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been
treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or
were refractory to such therapy or discontinued such therapy due to toxicity.